^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | sirpiglenastat (DRP-104) (Glutamine antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1572 - Broad glutamine pathway inhibition by DRP-104 results in anti-tumor activity in hypermetabolic lung tumors resistant to PD-1 or osimertinib therapy
Published date:
03/10/2021
Excerpt:
...we showed that DRP-104 induced a significant response in an OSI-resistant PDX model of EGFR mutant LUAD.
